SOMERSET, N.J. and
LA JOLLA, Calif., Oct 5 (Bernama-GLOBE NEWSWIRE) -- Catalent,
the leading global provider of advanced delivery technologies and development
solutions for drugs, biologics and consumer health products, and Triphase
Accelerator Corporation, a company dedicated to acquiring and developing novel
therapeutics for the treatment of cancer, today announced that Triphase will
obtain worldwide rights to further develop Catalent’s proprietary CD22-4AP
Antibody-Drug Conjugate (ADC), which has been developed by Catalent’s wholly
owned subsidiary, Redwood Bioscience, Inc., using its SMARTag™ technology
platform.
No comments:
Post a Comment